Cannabinoid Maker Brains Bioceutical Goes Public

The $750 million merger with Armada Acquisition would list Brains Therapeutics on Nasdaq as BAPI in 2027, pending approvals.

Updated on Nov. 6, 2026 in Biotech

Isometric editorial illustration of plain stainless-steel process vessels linked by clear tubing in a white-tiled production hall.
Cannabinoid maker Brains Bioceutical agreed to a $750 million merger with Armada Acquisition that would list the combined company on Nasdaq as BAPI in 2027. AI Illustration. Upload story photo >

Armada Acquisition has signed a definitive business combination agreement with Brains Bioceutical, which would take the cannabinoid and pharmaceutical ingredients maker public through a merger. The combined entity will be named Brains Therapeutics and list common shares on Nasdaq under the ticker BAPI. The deal is announced rather than completed, and remains subject to regulatory clearances, registration statements and shareholder votes from both companies.

Why it matters

The transaction is a route to public markets for a company that manufactures active pharmaceutical ingredients and develops therapies, and it values Brains Bioceutical at an implied pre-money equity value of about $750 million. It reflects a broader pattern of cannabinoid-focused firms seeking to reposition as pharmaceutical developers rather than consumer ingredient suppliers.

The deal sets an implied pre-money equity value of about $750 million for Brains Bioceutical, which holds an EU-GMP manufacturing facility through its subsidiary BSPG Laboratories. The source does not provide production volumes, clinical efficacy data or revenue figures, and those remain unknown.

The players

Armada Acquisition

A special purpose acquisition company whose merger with Brains Bioceutical would create the publicly listed Brains Therapeutics.

Brains Bioceutical

A developer and manufacturer of cannabinoid active pharmaceutical ingredients, operating an EU-GMP facility through its subsidiary BSPG Laboratories.

BSPG Laboratories

The wholly owned subsidiary of Brains Bioceutical that operates its EU-GMP manufacturing facility.

The details

Brains Bioceutical makes active pharmaceutical ingredients, the purified chemical compounds that give a drug its therapeutic effect, and develops finished pharmaceutical therapies from them. Its products include cannabinol, cannabidiol, cannabigerol, delta-8-THC and D9-THC, which are cannabinoids, naturally occurring compounds found in cannabis plants. The company's EU-GMP facility, meaning a plant certified under European good manufacturing practice standards, supports ingredient supply to animal health and nutraceutical customers. Its clinical pipeline includes an oral capsule for epilepsy and global rights to an extended-release methazolamide formulation for glaucoma.

Timeline

  1. November 6, 2026: Armada Acquisition and Brains Bioceutical announced the definitive business combination agreement.

  2. Second quarter of 2027: Scheduled completion of the deal and Nasdaq listing under BAPI.

The Tech Race

The merger places Brains Bioceutical among cannabinoid-focused companies pursuing pharmaceutical-grade manufacturing and clinical programs rather than consumer products alone. The source does not name specific competing firms or rival pipelines, so direct competitive positioning cannot be assessed.

The merger does not change any product available to consumers today, and the source gives no pricing or availability details for the pipeline candidates. Shareholders of both companies will vote on the deal, and Brains Bioceutical shareholders will roll their full equity into the new public company.

The takeaway

The deal shows cannabinoid manufacturers using public listings to move into pharmaceutical development, with the epilepsy capsule and glaucoma formulation as the clinical milestones to watch. The concrete item to track is whether the Q2 2027 closing and BAPI Nasdaq listing proceed after regulatory and shareholder approvals.

What happens next

The deal is scheduled to conclude in the second quarter of 2027, when the combined company is expected to begin trading on Nasdaq under the ticker BAPI.

Further reading

For broader context on how pharmaceutical developers are reaching public markets, see the Biotech section.

Source note: This article includes information reported by Pharmaceutical Technology.